PCSK9 Antagonist Patent Application by Argonaute RNA Limited

The EPO published patent application EP4081642A1 for an RNA-based PCSK9 antagonist developed by Argonaute RNA Limited. The application designates all European Patent Convention contracting states including DE, FR, GB, IT, NL, ES, BE, CH, and others. IPC classification C12N 15/113 indicates nucleic acid-based therapeutics.

Biotechnology and pharmaceutical companies developing cardiovascular or cholesterol-targeting therapeutics should review this patent for freedom-to-operate implications. The broad designation across EPO member states means the patent could affect commercialization activities in all covered European jurisdictions if the application proceeds to grant.